Comparative Pharmacology
Head-to-head clinical analysis: ESTINYL versus EVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTINYL versus EVEX.
ESTINYL vs EVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estinyl (ethinyl estradiol) is a synthetic estrogen that binds to estrogen receptors, leading to increased synthesis of DNA, RNA, and various proteins in target tissues. It suppresses gonadotropin release, modulating the hypothalamic-pituitary-ovarian axis.
Estrogen receptor agonist; binds to and activates nuclear estrogen receptors, leading to gene transcription and cellular effects in target tissues.
0.01-0.05 mg orally once daily for contraception or 2.5-10 mg orally 3-4 times daily for 5-10 days for hemostasis in dysfunctional uterine bleeding. Route: oral. Frequency: daily for contraception; multiple daily doses for acute bleeding.
0.625-1.25 mg orally once daily; or 0.3-0.625 mg vaginally once daily for 21 days with 7 days off.
None Documented
None Documented
Terminal elimination half-life is approximately 13-27 hours (mean ~17 hours); enterohepatic recirculation contributes to variability; steady-state achieved within 3-5 days.
Terminal elimination half-life is 12-24 hours, with a mean of approximately 18 hours. Due to significant enterohepatic recirculation, the half-life may be prolonged in patients with hepatic impairment or when administered with drugs that inhibit recirculation.
Renal excretion of metabolites (approximately 40-50% as ethinyl estradiol glucuronide and sulfate conjugates) and fecal excretion (approximately 20-30% as conjugates and minor metabolites); <10% excreted unchanged in urine.
Primarily hepatic metabolism with renal excretion of metabolites; approximately 60% of a dose is excreted in urine as conjugates (glucuronides and sulfates) and 30% in feces via biliary elimination. Less than 5% is excreted unchanged in urine.
Category C
Category C
Estrogen
Estrogen